Stock Financial Ratios, Dividends, Split History

WFM / Whole Foods Market, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price41.68
Volume9,347,100.00
Market Cap ($M)0.00
Book Value ($M)3,430.00
Book Value / Share34,300,000.00
Price / Book0.00
NCAV ($M)-1,101.00
NCAV / Share-11,010,000.00
Price / NCAV-0.00
Share Statistics
Common Stock Shares Outstanding 100
Common Shares Outstanding 100
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Assets6,676.00
Liabilities3,246.00
Quick Ratio1.24
Current Ratio1.58
Income Statement (mra) ($M)
Sales Revenue Net16,030,000,000.00
Operating Income459.00
Net Income245.00
Cash Flow Statement (mra) ($M)
Cash From Operations1,138.00
Cash from Investing-906.00
Cash from Financing1,138.00
Identifiers and Descriptors
CUSIP966837106
Central Index Key (CIK)865436
Related CUSIPS
096683710 966837906 010534372 966837956
Industry Groups
SIC 5411 - Grocery Stores

Split History

Stock splits are used by Whole Foods Market, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Alphabet Roundup: JD Investment, Carrefour Partnership, Waymo

15h zacks
Alphabet’s (GOOGL - Free Report) strategic investment in China’s JD.com (JD - Free Report) and its Carrefour partnership boost its Google Shopping service while the completion of Waymo’s year-long experiment with riders take it a step closer to launching the self-driving taxi service. Here are the details- (53-0)

Alphabet Inc Versus Amazon.com, Inc. Stock: Which Is the Better Buy?

16h investorplace
When it comes to Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) and Amazon.com, Inc. (NASDAQ:AMZN), there are a number of similarities. Both companies are tech titans. Amazon stock has the second-highest market cap in the world; GOOGL stock is third. (299-2)

Amazon’s clever machines are moving from the warehouse to headquarters

2018-06-18 livemint
Seattle: Amazon.com Inc. has long used robots to help humans move merchandise around its warehouses. Now automation is transforming Amazon’s white-collar workforce, too. (12-0)

Britain’s Robot Grocer Is Coming to the U.S. - Bloomberg

2018-06-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (63-0)

5 Retail Stocks on a Tear: See Who’s Leading the Race

2018-06-14 investorplace
Online retail sales continue to soar, with bellwether Amazon.com, Inc.’s (NASDAQ:AMZN) market cap topping $800 billion. But, their outsized gains haven’t hampered traditional retailers much. All of retailers have been part of a broad-based rally so far this year but hardly any of them are trading near peak levels. Obviously, they have more room to run and this growth narrative is well supported by strong fundamentals. (308-0)

CUSIP: 966837106